Faruqi and Faruqui, LLP Logo
Share this page

Akorn, Inc. (AKRX)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Akorn, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ:AKRX).

On February 26, 2018, Fresenius SE & Co. KGaA (“Fresenius”), the company that previously agreed to acquire Akorn, announced that it “is conducting an independent investigation, using external experts, into alleged breaches of [U.S. Food and Drug Administration] data integrity requirements relating to product development at Akorn[.]”  Fresenius further stated that it “will assess the findings of th[e] investigation” and that “[t]he consummation of the transaction may be affected if the closing conditions under the merger agreement are not met.”

On this news, Akorn’s share price significantly declined, causing harm to investors.

If you invested in Akorn stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Akorn, Inc. (AKRX)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 03/01/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.